Yourgene Health Share Discussion Threads

[christopher logsdon] 12/6/2019 11:33

I hope you're right Scotty I've been waiting forever..... i'm confident it will get better but it's just taking longer than expected. All the best

[scotty1] 12/6/2019 07:51

Chart wise starting to look a little interesting, certainly one to watch closely the next few weeks as I would imagine the share price will creep up as we approach the results in early July and the research note from the new brokers which will be very upbeat imo.

[scotty1] 11/6/2019 10:17

Offer price moving up,tick up coming ?

[scotty1] 09/6/2019 21:17

Fair enough twix but in his short time at the Helm i believe LR as delivered in what he as achieved with Illumina and Thermo Fisher,now that's all cleared he can concentrate on other aspects of the business ie for starters the acquisition of Elucigene,and i'm confident he will deliver a lot more.

[twix386] 09/6/2019 15:02

Yes, TW has been atrocious on tipping and revisions. Nobody should applaud!I hope Stifel has grounds to raise target. With no NIPT deal worthy of rns for over a year we need more delivered and I hope that will come with results and some material overdue commercial news now Lyn Reece has cleared the long running impediments. You may have noted I was almost alone in recommending SL be replaced over a year ago. I am pleased it finally happened and not one complaint about our new guy. When people deliver I don't complain. When they don't, I do!!!

[scotty1] 09/6/2019 14:55

17p+

Anyhow what does it matter what tp he as set you do nothing but moan and groan about TW anyways.

I'd have thought when the new note comes out the tp will be quite a bit higher than TWs and for me their tp will have a lot more clout than TWs tp for obvious reasons.

[twix386] 09/6/2019 14:30

Still, if his target is now down to 17p then i guess you could just about have that iro nearly 50%. Just damn disappointing to hear that after all the previous targets St 25p its come down to 17p after so many failed attempts, delays and dilution. I hope this time we do see it delivered as any more delays and missed targets and we will be lucky not to see a target below 15p. It's been shocking these last few years even if since Lynn Rees has pulled us up by our bootstraps!

[twix386] 09/6/2019 14:20

Well that excerpt was copied word for word from an email TW sent out advertising his site with trailors for his crowing over Neil woodford, YoutGene as copied etc. Copied word for word

[scotty1] 09/6/2019 13:59

Well I have read that piece and cannot see were he mentions 50% in short order,he does mention 17p+

[twix386] 09/6/2019 11:12

A question.Today TW has stated...."Today we run details of a chat with Adam Reynolds at Yourgene about why he has just bought so many shares and why the share price could rocket by almost 50% in short order."What is TW's current revised stated price target?Wasn't it iro 20p? Down from past targets after delays and dilution.So, with today's almost 50% hope that would reveal iro 15p!!! Ticketing half the price target I had him set at??

[scotty1] 07/6/2019 11:07

Press Release

New York, NY -- (SBWIRE) -- 06/06/2019

Kidney Function Test Market Share, Growth and Analysis by Key Players: Abbott Laboratories. St. Jude Medical, CareDx, Beckman Coulter, Siemens Healthcare GmbH
According to a study and analysis by Reports and Data, the global Kidney Function Test market was valued at USD 656.6 Million in 2018 and is expected to be USD 1061.0 million by the end of the forecasting period of 2026, at a CAGR of 6.2%.

The market is witnessing high growth due to increasing number of Kidney testing functions for patients suffering from kidney malfunctions mainly due to changing lifestyles. The kidney is an essential organ which refines the fluids in our body before distributing them and a malfunction can lead to various stages of cancer and chronic disease.

Scope of the Report:
The research methodologies used for evaluating the Kidney Function Test market are inventive and also provides enough evidence on the demand and supply status, production capability, import and export, supply chain management and investment feasibility.

The investigative approach applied for the extensive analysis of the sale, gross margin and profit generated by the industry are presented through resources including tables, charts, and graphic images. Importantly, these resources can be easily integrated or used for preparing business or corporate presentations.

Companies considered and profiled in this market study
The companies that are considered in this market study are Abbott Laboratories. St. Jude Medical, CareDx, Beckman Coulter, Siemens Healthcare GmbH, Cook Medical, Baxter, Merck and Company, Yourgene Health and Pfizer.

[scotty1] 07/6/2019 10:46

Should get a turnaround this afternoon and a flat or blue finish 😉

[the monkster] 06/6/2019 21:12

Buy buy buy. Shackles are off

[scotty1] 06/6/2019 15:13

Could be mhw,getting in before the 30 day closed period seeing as results due early July,we will see.

[scotty1] 06/6/2019 15:11

Need sellers as well as buyers to make a market.

[hjb1] 06/6/2019 15:01

some still offloading too!

[mhw28865] 06/6/2019 14:16

Big chunky trades going through wouldnt be surprised to see a directors buy RNS popping up later or in the morning

[rathean] 06/6/2019 12:04

Doubled up this morning after banking profit on #CIR bounce. Big war chest, increasing revenues just a great growth story. Looking at circa 20p target imo dyor ofc.

[scrutable] 06/6/2019 11:27

Every trade so far today has been a buy.

[mhw28865] 06/6/2019 11:27

Nice flurry of buys today lets hope the seller has finished and we can start getting back to 20s

[scotty1] 06/6/2019 08:39

Online offer moving up again,watch this space 😉

[scotty1] 05/6/2019 14:54

All quite in here,meanwhile offer price moving up,come on chaps a couple more buys should see us tick up 😜

[scotty1] 03/6/2019 08:34

Friday 31 May 2019

The most reliable early guide is substantial buying by the directors. They are not able to buy or sell shares in their company during “closed periods” – the two months before the announcement of the half-year and full-year results. They are also prohibited from buying or selling shares if they possess any undisclosed inside information such as news of a possible takeover, a significant share issue or the win or loss of a particularly large contract. In the months surrounding the results, the directors’ dealings that are usually the most meaningful are those that are just before the start of the closed period or just after it has finished.